Accuray, the maker of the CyberKnife and other radiation oncology technology, appointed Gregory Lichtwardt as executive VP and chief financial officer after Derek Bertocci resigned as senior VP and CFO Sept. 2.
Lichtwardt, 59, comes to Sunnyvale, Calif.-based Accuray from Conceptus, where he likewise was executive VP and CFO. Conceptus, known for a permanent nonsurgical birth control method for women, was acquired by Bayer in June in a deal valued at $1.1 billion.
Bertocci joined Accuray in January 2009. In a news release announcing the leadership change, the company credits him with helping to expand the market for the CyberKnife and helping steer the company through the 2011 acquisition of TomoTherapy, a technology that uses CT imaging to guide radiation treatment of tumors, for $277 million.
Accuray's operating loss was $80.7 million on $316 million in revenue for its fiscal 2013, ended June 30. The company attributed some of that figure to a restructuring effort and stressed that losses narrowed in the fourth quarter. Executives also reported strong orders booked at the end of the year for CyberKnife and TomoTherapy systems.
“This is an exciting time to be joining Accuray,” Lichtwardt said in the release. “The company has made significant strides, is led by a talented team and is positioned to achieve significant growth.”